Short Interest in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Increases By 24.0%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,550,000 shares, an increase of 24.0% from the March 15th total of 1,250,000 shares. Approximately 3.2% of the company’s stock are sold short. Based on an average trading volume of 2,210,000 shares, the days-to-cover ratio is currently 0.7 days.

Cardio Diagnostics Stock Performance

CDIO stock opened at $0.37 on Tuesday. The business has a 50 day moving average price of $0.43 and a 200 day moving average price of $0.49. Cardio Diagnostics has a fifty-two week low of $0.19 and a fifty-two week high of $1.77.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in shares of Cardio Diagnostics during the fourth quarter worth about $236,000. Geode Capital Management LLC boosted its stake in Cardio Diagnostics by 97.6% during the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock worth $334,000 after purchasing an additional 179,978 shares during the period. Jane Street Group LLC purchased a new position in Cardio Diagnostics during the 4th quarter worth $103,000. Finally, Two Sigma Securities LLC acquired a new position in Cardio Diagnostics in the fourth quarter valued at $48,000. Institutional investors and hedge funds own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.